Clinical trial · no report yet · Phase 3
PEACE III
Phase III Radium 223 mCRPC-PEACE III
- NCT02194842 ↗
- Active not recruiting
- European Organisation for Research and Treatment of Cancer - EORTC
- 20 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 10 | |
| X threads | 8 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Prostate Cancer
- Interventions
- Ra223; Enzalutamide
- Arms
- Enzalutamide · Active comparator
- Enzalutamide and Ra223 · Experimental
- Enrollment
- 446
- Primary outcomes
- radiological progression-free survival
- progression-free survival per Blinded Independent Central Review (PFS1B)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC with Bayer, Astellas Pharma Europe Ltd., UNICANCER, Canadian Urologic Oncology Group, Latin American Cooperative Oncology Group, Cancer Trials Ireland
- Start
- Oct 2015
- Primary completion
- Feb 19, 2024
- Results posted
- No
- Registry record
- NCT02194842 · updated Sep 19, 2025
Publications
linked from the registry- Tombal B, Saad F, Gallardo E, Soares A, Loriot Y, McDermott R, Briers E, Lagstrom M, Coens C, Poncet C, Fournier B, Gillessen S. A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases. Future Oncol. 2025 Dec;21(30):3845-3858. doi: 10.1080/14796694.2025.2592722. Epub 2025 Nov 28. PubMed 41313045
- Gillessen S, Tombal B, Turco F, Choudhury A, Rodriguez-Vida A, Gallardo E, Velho PI, Nole F, Cruz F, Loriot Y, McDermott R, Roumeguere T, Daugaard G, Yamamura R, Bompas E, Maroto P, Polo MH, da Trindade KM, Preto DD, Skoneczna I, Lecouvet F, Coens C, Fournier B, Saad F. Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis. Eur Urol. 2025 Mar;87(3):285-288. doi: 10.1016/j.eururo.2024.11.027. Epub 2025 Jan 17. PubMed 39827019